Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» JAMA
JAMA
JAMA: Leqembi could cost Medicare up to $5B per year
JAMA: Leqembi could cost Medicare up to $5B per year
Medical Marketing and Media
Biogen
Eisai
Leqembi
drug pricing
Medicare
Alzheimer's disease
JAMA
Flag link:
Study: Half of confirmatory studies for accelerated approvals are late
Study: Half of confirmatory studies for accelerated approvals are late
RAPS.org
JAMA
regulatory
accelerated approvals
Flag link:
Study finds manufacturers spend more to advertise less beneficial drugs
Study finds manufacturers spend more to advertise less beneficial drugs
RAPS.org
JAMA
DTC advertising
pharma advertising
Flag link:
Broken promises? FDA needs more power to remove drugs from marketplace, JAMA analysis finds
Broken promises? FDA needs more power to remove drugs from marketplace, JAMA analysis finds
Endpoints
JAMA
FDA
clinical trials
Flag link:
Study: Public funding was instrumental to early development of COVID therapeutics, vaccines
Study: Public funding was instrumental to early development of COVID therapeutics, vaccines
RAPS.org
COVID-19
pandemic
JAMA
funding
vaccines
Flag link:
JAMA study finds cancer drug data is still largely unavailable to qualified researchers
JAMA study finds cancer drug data is still largely unavailable to qualified researchers
Endpoints
JAMA
oncology
cancer
clinical trials
Flag link:
A New JAMA Study Misleads About Drug Prices—And Launches a New Attack on Patients with Ultra-Rare Diseases
A New JAMA Study Misleads About Drug Prices—And Launches a New Attack on Patients with Ultra-Rare Diseases
Drug Channels
JAMA
drug pricing
Flag link:
Study: FDA approves new oncology drugs quicker than EMA
Study: FDA approves new oncology drugs quicker than EMA
RAPS.org
JAMA
regulatory
drug approvals
FDA
EMA
Europe
Flag link:
JAMA Paper Withdrawal Adds One More Layer to Aduhelm Controversy
JAMA Paper Withdrawal Adds One More Layer to Aduhelm Controversy
BioSpace
Biogen
Aduhelm
Alzheimer's disease
JAMA
Flag link:
FDA staffers defend Aduhelm approval in JAMA editorial
FDA staffers defend Aduhelm approval in JAMA editorial
Pharmaforum
FDA
Biogen
Aduhelm
JAMA
drug approvals
Alzheimer's disease
Flag link:
Americans Are Dying In The Pandemic At Rates Far Higher Than In Other Countries
Americans Are Dying In The Pandemic At Rates Far Higher Than In Other Countries
NPR
pandemic
COVID-19
JAMA
Flag link:
Policy makers should ‘set their sights higher’ on U.S. drug pricing regulations, researchers say
Policy makers should ‘set their sights higher’ on U.S. drug pricing regulations, researchers say
MedCity News
drug pricing
JAMA
legislation
Flag link:
Merck CEO Frazier finds fault in new studies suggesting pharma profits are too high
Merck CEO Frazier finds fault in new studies suggesting pharma profits are too high
Fierce Pharma
JAMA
profits
Merck
Ken Frazier
Pharma CEOs
Flag link:
Researchers Call on FDA to Rethink Guidance Allowing Use of Surrogate Outcomes
Researchers Call on FDA to Rethink Guidance Allowing Use of Surrogate Outcomes
RAPS.org
FDA
JAMA
infectious diseases
drug development
surrogate endpoints
Flag link:
JAMA: Withdraw This Flawed and Inaccurate Article About the 340B Program and Drug Prices
JAMA: Withdraw This Flawed and Inaccurate Article About the 340B Program and Drug Prices
Drug Channels
JAMA
drug pricing
340B
hepatitis C
Flag link:
Financial disclosure lacking in publication of clinical trials, study finds
Financial disclosure lacking in publication of clinical trials, study finds
Science Daily
oncologists
physicians
physician payments
JAMA
scientific journals
cancer
Flag link:
Copay exceeds drug cost in 23% of claims: JAMA research
Copay exceeds drug cost in 23% of claims: JAMA research
Biopharma Dive
copays
JAMA
drug pricing
Flag link:
Doctors with restricted sales-rep access prescribed fewer promoted meds: JAMA
Doctors with restricted sales-rep access prescribed fewer promoted meds: JAMA
Fierce Pharma
physicians
drug reps
physician access
JAMA
Flag link:
Amgen refutes 'flawed' cholesterol study
Amgen refutes 'flawed' cholesterol study
BioPharma Dive
Amgen
PCSK9 inhibitors
JAMA
Repatha
Flag link:
Are PCSK9 meds worth the cost? Only if Amgen, Sanofi and Regeneron slash prices by two-thirds: JAMA
Are PCSK9 meds worth the cost? Only if Amgen, Sanofi and Regeneron slash prices by two-thirds: JAMA
Fierce Pharma
PCSK9 inhibitors
Amgen
Sanofi
Regeneron
Praluent
Repatha
JAMA
drug pricing
Flag link:
Pages
1
2
next ›
last »